Therapeutic Complement Inhibition: New Developments

 

 Buy Article Permissions and Reprints

ABSTRACT

Activation of the complement system significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases. Current strategies to inhibit complement include the replacement or substitution of endogenous soluble complement inhibitors (e.g., C1 inhibitor [C1 inh], recombinant soluble complement receptor 1, TP10), the administration of antibodies to block key proteins of the cascade reaction (e.g., C5) or to neutralize the action of the complement-derived anaphylatoxins, or blockade of complement receptors (e.g., C5aR, CD88). The recent approvals of anti-C5 for the treatment of paroxysmal nocturnal hemoglobinuria as well as of C1 inh for the treatment of hereditary angioedema beyond European countries have provided a resurgence of interest in the potential of complement therapeutics for the treatment of disease.

REFERENCES

• 1 Walport M J. Complement. First of two parts.  N Engl J Med. 2001;  344(14) 1058-1066
  CrossrefPubMedGoogle Scholar
• 2 Walport M J. Complement. Second of two parts.  N Engl J Med. 2001;  344(15) 1140-1144
  CrossrefPubMedGoogle Scholar
• 3 Sjöberg A P, Trouw L A, Blom A M. Complement activation and inhibition: a delicate balance.  Trends Immunol. 2009;  30(2) 83-90
  CrossrefPubMedGoogle Scholar
• 4 Markiewski M M, Lambris J D. The role of complement in inflammatory diseases from behind the scenes into the spotlight.  Am J Pathol. 2007;  171(3) 715-727
  CrossrefPubMedGoogle Scholar
• 5 Holers V M. The spectrum of complement alternative pathway-mediated diseases.  Immunol Rev. 2008;  223 300-316
  CrossrefPubMedGoogle Scholar
• 6 Nussenblatt R B, Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease.  Curr Opin Investig Drugs. 2009;  10(5) 434-442
  PubMedGoogle Scholar
• 7 Ricklin D, Lambris J D. Complement-targeted therapeutics.  Nat Biotechnol. 2007;  25(11) 1265-1275
  CrossrefPubMedGoogle Scholar
• 8 Mollnes T E, Kirschfink M. Strategies of therapeutic complement inhibition.  Mol Immunol. 2006;  43(1-2) 107-121
  CrossrefPubMedGoogle Scholar
• 9 Davis III A E. The pathophysiology of hereditary angioedema.  Clin Immunol. 2005;  114(1) 3-9
  CrossrefPubMedGoogle Scholar
• 10 Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.  Trends Mol Med. 2009;  15(2) 69-78
  CrossrefPubMedGoogle Scholar
• 11 Kirschfink M, Mollnes T E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential.  Expert Opin Pharmacother. 2001;  2(7) 1073-1083
  CrossrefPubMedGoogle Scholar
• 12 Beinrohr L, Dobó J, Závodszky P, Gál P. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation.  Trends Mol Med. 2008;  14(12) 511-521
  CrossrefPubMedGoogle Scholar
• 13 Müller-Eberhard H J. Molecular organization and function of the complement system.  Annu Rev Biochem. 1988;  57 321-347
  CrossrefPubMedGoogle Scholar
• 14 Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes.  Annu Rev Med. 2008;  59 293-309
  CrossrefPubMedGoogle Scholar
• 15 Taylor P R, Carugati A, Fadok V A et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo.  J Exp Med. 2000;  192(3) 359-366
  CrossrefPubMedGoogle Scholar
• 16 Botto M, Kirschfink M, Macor P, Pickering M C, Würzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies.  Mol Immunol. 2009;  46(14) 2774-2783
  CrossrefPubMedGoogle Scholar
• 17 Thiel S, Gadjeva M. Humoral pattern recognition molecules: mannan-binding lectin and ficolins.  Adv Exp Med Biol. 2009;  653 58-73
  PubMedGoogle Scholar
• 18 Undar A, Fraser Jr C D. Anti-factor D monoclonal antibody, pulsatile flow and cardiotomy suction during cardiopulmonary bypass.  Eur J Cardiothorac Surg. 2002;  22(2) 330-331 discussion 331
  CrossrefPubMedGoogle Scholar
• 19 Taube C, Thurman J M, Takeda K et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation.  Proc Natl Acad Sci U S A. 2006;  103(21) 8084-8089
  CrossrefPubMedGoogle Scholar
• 20 Kemper C, Hourcade D E. Properdin: new roles in pattern recognition and target clearance.  Mol Immunol. 2008;  45(16) 4048-4056
  CrossrefPubMedGoogle Scholar
• 21 Hourcade D E. Properdin and complement activation: a fresh perspective.  Curr Drug Targets. 2008;  9(2) 158-164
  CrossrefPubMedGoogle Scholar
• 22 Gupta-Bansal R, Parent J B, Brunden K R. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies.  Mol Immunol. 2000;  37(5) 191-201
  CrossrefPubMedGoogle Scholar
• 23 Ricklin D, Lambris J D. Compstatin: a complement inhibitor on its way to clinical application.  Adv Exp Med Biol. 2008;  632 273-292
  PubMedGoogle Scholar
• 24 Sahu A, Morikis D, Lambris J D. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.  Mol Immunol. 2003;  39(10) 557-566
  CrossrefPubMedGoogle Scholar
• 25 Nilsson B, Larsson R, Hong J et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.  Blood. 1998;  92(5) 1661-1667
  PubMedGoogle Scholar
• 26 Lazar H L, Keilani T, Fitzgerald C A TP10 Cardiac Surgery Study Group et al. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?.  Circulation. 2007;  116(11, Suppl) I83-I88
  PubMedGoogle Scholar
• 27 Hillmen P, Muus P, Dührsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.  Blood. 2007;  110(12) 4123-4128
  CrossrefPubMedGoogle Scholar
• 28 Dubois E A, Cohen A F. Eculizumab.  Br J Clin Pharmacol. 2009;  68(3) 318-319
  CrossrefPubMedGoogle Scholar
• 29 Lappegård K T, Christiansen D, Pharo A et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature.  Proc Natl Acad Sci U S A. 2009;  106(37) 15861-15866
  CrossrefPubMedGoogle Scholar
• 30 Risitano A M, Notaro R, Marando L et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.  Blood. 2009;  113(17) 4094-4100
  CrossrefPubMedGoogle Scholar
• 31 Patel S. Combination therapy for age-related macular degeneration.  Retina. 2009;  29(6, Suppl) S45-S48
  CrossrefPubMedGoogle Scholar
• 32 Monk P N, Scola A M, Madala P, Fairlie D P. Function, structure and therapeutic potential of complement C5a receptors.  Br J Pharmacol. 2007;  152(4) 429-448
  CrossrefPubMedGoogle Scholar
• 33 Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma.  Proc Natl Acad Sci U S A. 2007;  4(3) 247-251
  PubMedGoogle Scholar
• 34 Sheerin N S, Risley P, Abe K et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury.  FASEB J. 2008;  22(4) 1065-1072
  CrossrefPubMedGoogle Scholar
• 35 Smith R A. Targeting anticomplement agents.  Biochem Soc Trans. 2002;  30(Pt 6) 1037-1041
  CrossrefPubMedGoogle Scholar
• 36 Souza D G, Esser D, Bradford R, Vieira A T, Teixeira M M. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.  Br J Pharmacol. 2005;  145(8) 1027-1034
  CrossrefPubMedGoogle Scholar
• 37 Banz Y, Hess O M, Robson S C et al. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1.  Cardiovasc Res. 2007;  76(3) 482-493
  CrossrefPubMedGoogle Scholar
• 38 Szakonyi G, Guthridge J M, Li D, Young K, Holers V M, Chen X S. Structure of complement receptor 2 in complex with its C3d ligand.  Science. 2001;  292(5522) 1725-1728
  CrossrefPubMedGoogle Scholar
• 39 Huang Y, Qiao F, Atkinson C, Holers V M, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.  J Immunol. 2008;  181(11) 8068-8076
  PubMedGoogle Scholar
• 40 Atkinson C, Qiao F, Song H, Gilkeson G S, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.  J Immunol. 2008;  180(2) 1231-1238
  PubMedGoogle Scholar
• 41 Song H, Qiao F, Atkinson C, Holers V M, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.  J Immunol. 2007;  179(11) 7860-7867
  PubMedGoogle Scholar
• 42 Rohrer B, Long Q, Coughlin B et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.  Invest Ophthalmol Vis Sci. 2009;  50(7) 3056-3064
  CrossrefPubMedGoogle Scholar
• 43 Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma.  Am J Pathol. 2006;  169(3) 1039-1047
  CrossrefPubMedGoogle Scholar
• 44 Atkinson C, Song H, Lu B et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.  J Clin Invest. 2005;  115(9) 2444-2453
  CrossrefPubMedGoogle Scholar
• 45 Seelen M A, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA.  J Immunol Methods. 2005;  296(1–2) 187-198
  CrossrefPubMedGoogle Scholar
• 46 Banda N K, Levitt B, Glogowska M J et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.  J Immunol. 2009;  183(9) 5928-5937
  CrossrefPubMedGoogle Scholar

Michael KirschfinkD.V.M. Ph.D. 

Institute of Immunology, University of Heidelberg

Im Neuenheimer Feld 305, 69120 Heidelberg, Germany

Email: kirschfink@uni-hd.de